Moneycontrol PRO
LAMF
LAMF

Macquarie Research

Jump to
  • Macquarie downgrades Eicher Motors to neutral

  • Market valuations high; affordable housing may spring a surprise: Macquarie

  • Demonetisation: Cos may cut full-yr guidance; Q3 to be a washout, says Macquarie

  • Sentiment to turn +ve for L&T in H2; buy IRB: Macquaire

  • Modi's Q1 show: Govt scores healthy 8.5/10, says Macquarie

  • Adobe results beat as subscription model gains traction

    Adobe Systems Inc , maker of Photoshop and Acrobat software, reported quarterly results that beat analysts' average estimates as revenue from subscriptions more than doubled, sending its shares up 7 percent in extended trade.

  • Facebook stock avoids steep drop as Street rethinks results

    Shares of Facebook Inc recovered from an 8 percent slide on Thursday, finishing the regular session down less than 1 percent, as Wall Street's initial alarm over mobile revenue results and spending plans subsided.

  • SBI will require capital in FY12 or early FY13: Macquarie

    Head of financial research at Macquarie Research, Suresh Ganapathy told CNBC-TV18 that the rate of accretion of non-performing loans (NPLs) at margins could see a slowdown. He feels that SBI should raise capital in FY12 or at the beginning of FY13; otherwise, they will have issue to grow their book.

  • SBI's operational numbers are disappointing: Macquarie

    State Bank of India's Q4 net profit tumbled nearly 99% year-on-year to Rs 21 crore. In an interview with CNBC-TV18, Suresh Ganapathy, Banking Analyst, Macquarie Research says, asset quality has deteriorated a bit this quarter and that is the reason provisioning has gone up. “Numbers have really disappointed even on the operational front,” he adds.

  • Glenmark Pharma a top pick in pharma space: Macquarie

    In an exclusive interview with CNBC TV-18's Udayan Mukherjee and Mitali Mukherjee, Abhishek Singhal of Macquarie, said that Glenmark would be his top pick in the Indian pharma space since sentiment is positive for the pharma firm after its pact with pharma major Sanofi.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347